Investors

Latest Financial Results

2023

Year End Results

Ended Oct 31, 2023

Stock Information

Symbol

ANIX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.  Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.  The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer.  These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.  Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization. 

Logo Itus

Latest News & Events

Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial

Read More...

Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference

Read More...

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology

Read More...